WO2008113870A1 - Método de diagnóstico y/o pronóstico de cancer vesical - Google Patents
Método de diagnóstico y/o pronóstico de cancer vesical Download PDFInfo
- Publication number
- WO2008113870A1 WO2008113870A1 PCT/ES2007/000330 ES2007000330W WO2008113870A1 WO 2008113870 A1 WO2008113870 A1 WO 2008113870A1 ES 2007000330 W ES2007000330 W ES 2007000330W WO 2008113870 A1 WO2008113870 A1 WO 2008113870A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bladder
- genes
- gene
- bladder cancer
- quantification
- Prior art date
Links
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 title claims abstract description 119
- 238000000034 method Methods 0.000 title claims abstract description 83
- 238000004393 prognosis Methods 0.000 title claims abstract description 39
- 238000003745 diagnosis Methods 0.000 title claims abstract description 31
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 226
- 206010005003 Bladder cancer Diseases 0.000 claims abstract description 107
- 201000005112 urinary bladder cancer Diseases 0.000 claims abstract description 104
- 230000014509 gene expression Effects 0.000 claims abstract description 99
- 239000000523 sample Substances 0.000 claims abstract description 92
- 239000012530 fluid Substances 0.000 claims abstract description 73
- 238000001514 detection method Methods 0.000 claims abstract description 69
- 238000000338 in vitro Methods 0.000 claims abstract description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 161
- 238000011002 quantification Methods 0.000 claims description 64
- 101000775052 Homo sapiens Protein AHNAK2 Proteins 0.000 claims description 48
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 claims description 47
- 102100032700 Keratin, type I cytoskeletal 20 Human genes 0.000 claims description 46
- 101000994460 Homo sapiens Keratin, type I cytoskeletal 20 Proteins 0.000 claims description 45
- 101001005719 Homo sapiens Melanoma-associated antigen 3 Proteins 0.000 claims description 44
- 102100025947 Insulin-like growth factor II Human genes 0.000 claims description 44
- 102100021752 Corticoliberin Human genes 0.000 claims description 42
- 102100025082 Melanoma-associated antigen 3 Human genes 0.000 claims description 42
- 101000869031 Homo sapiens Cathepsin E Proteins 0.000 claims description 40
- 101001139112 Homo sapiens Krueppel-like factor 9 Proteins 0.000 claims description 40
- 102100037765 Periostin Human genes 0.000 claims description 40
- 102100031838 Protein AHNAK2 Human genes 0.000 claims description 40
- 102100032215 Cathepsin E Human genes 0.000 claims description 39
- 101000768069 Homo sapiens Annexin A10 Proteins 0.000 claims description 39
- 101000866308 Homo sapiens Excitatory amino acid transporter 4 Proteins 0.000 claims description 39
- 102100020684 Krueppel-like factor 9 Human genes 0.000 claims description 39
- 102100028117 Annexin A10 Human genes 0.000 claims description 38
- 101001095308 Homo sapiens Periostin Proteins 0.000 claims description 38
- 102000012985 SLC1A6 Human genes 0.000 claims description 37
- 102100022443 CXADR-like membrane protein Human genes 0.000 claims description 36
- 102220510525 Retinoic acid receptor alpha_R14D_mutation Human genes 0.000 claims description 27
- 101100189627 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PTC5 gene Proteins 0.000 claims description 27
- 101100082911 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ppp1 gene Proteins 0.000 claims description 27
- 239000003550 marker Substances 0.000 claims description 25
- 101000583797 Homo sapiens Protein MCM10 homolog Proteins 0.000 claims description 21
- 210000002700 urine Anatomy 0.000 claims description 21
- 201000011510 cancer Diseases 0.000 claims description 19
- 102100024202 Protein phosphatase 1 regulatory subunit 14D Human genes 0.000 claims description 17
- 101000688355 Homo sapiens Protein phosphatase 1 regulatory subunit 14D Proteins 0.000 claims description 16
- 102100030962 Protein MCM10 homolog Human genes 0.000 claims description 11
- 101100137243 Homo sapiens POSTN gene Proteins 0.000 claims description 9
- 101150023743 KLF9 gene Proteins 0.000 claims description 8
- -1 TERT Proteins 0.000 claims description 7
- 238000009007 Diagnostic Kit Methods 0.000 claims description 6
- 101150117667 PPP1R14D gene Proteins 0.000 claims description 4
- 101000581402 Homo sapiens Melanin-concentrating hormone receptor 1 Proteins 0.000 claims description 3
- 102000037055 SLC1 Human genes 0.000 claims description 3
- 101000895481 Homo sapiens Corticoliberin Proteins 0.000 claims 18
- XXQGYGJZNMSSFD-UHFFFAOYSA-N 2-[2-(dimethylcarbamoyl)phenoxy]acetic acid Chemical compound CN(C)C(=O)C1=CC=CC=C1OCC(O)=O XXQGYGJZNMSSFD-UHFFFAOYSA-N 0.000 claims 16
- 238000003753 real-time PCR Methods 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 abstract description 14
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 210000003932 urinary bladder Anatomy 0.000 description 107
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 42
- 238000002493 microarray Methods 0.000 description 33
- 238000011529 RT qPCR Methods 0.000 description 28
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 25
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 25
- 101000901723 Homo sapiens CXADR-like membrane protein Proteins 0.000 description 25
- 229940041967 corticotropin-releasing hormone Drugs 0.000 description 24
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 23
- 230000035945 sensitivity Effects 0.000 description 20
- 238000003491 array Methods 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 230000015556 catabolic process Effects 0.000 description 12
- 238000006731 degradation reaction Methods 0.000 description 12
- 239000002299 complementary DNA Substances 0.000 description 11
- 230000007170 pathology Effects 0.000 description 10
- 230000002485 urinary effect Effects 0.000 description 10
- 238000002405 diagnostic procedure Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 7
- 210000004877 mucosa Anatomy 0.000 description 7
- 201000009030 Carcinoma Diseases 0.000 description 6
- 102100032938 Telomerase reverse transcriptase Human genes 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 description 5
- 230000006399 behavior Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000009545 invasion Effects 0.000 description 5
- 206010044412 transitional cell carcinoma Diseases 0.000 description 5
- 102100036961 Nuclear mitotic apparatus protein 1 Human genes 0.000 description 4
- 238000002123 RNA extraction Methods 0.000 description 4
- 108010017842 Telomerase Proteins 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 108010036112 nuclear matrix protein 22 Proteins 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000002271 resection Methods 0.000 description 4
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 3
- 238000000018 DNA microarray Methods 0.000 description 3
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 201000001531 bladder carcinoma Diseases 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000009799 cystectomy Methods 0.000 description 3
- 238000002574 cystoscopy Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 238000003633 gene expression assay Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 201000004933 in situ carcinoma Diseases 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 3
- 208000023747 urothelial carcinoma Diseases 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 102100026031 Beta-glucuronidase Human genes 0.000 description 2
- 208000009458 Carcinoma in Situ Diseases 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- 102100031559 Excitatory amino acid transporter 4 Human genes 0.000 description 2
- 102100028953 Gelsolin Human genes 0.000 description 2
- 101000933465 Homo sapiens Beta-glucuronidase Proteins 0.000 description 2
- 101001059150 Homo sapiens Gelsolin Proteins 0.000 description 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 2
- 102100030979 Methylmalonyl-CoA mutase, mitochondrial Human genes 0.000 description 2
- 101710199268 Periostin Proteins 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 101150084279 TM gene Proteins 0.000 description 2
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000007479 molecular analysis Methods 0.000 description 2
- 238000001823 molecular biology technique Methods 0.000 description 2
- 238000010827 pathological analysis Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 108020004418 ribosomal RNA Proteins 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 101150072531 10 gene Proteins 0.000 description 1
- 101150082072 14 gene Proteins 0.000 description 1
- AQQSXKSWTNWXKR-UHFFFAOYSA-N 2-(2-phenylphenanthro[9,10-d]imidazol-3-yl)acetic acid Chemical compound C1(=CC=CC=C1)C1=NC2=C(N1CC(=O)O)C1=CC=CC=C1C=1C=CC=CC=12 AQQSXKSWTNWXKR-UHFFFAOYSA-N 0.000 description 1
- 101150092807 ANXA10 gene Proteins 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 102000017620 Annexin A10 Human genes 0.000 description 1
- 108050005848 Annexin A10 Proteins 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000004178 Cathepsin E Human genes 0.000 description 1
- 108090000611 Cathepsin E Proteins 0.000 description 1
- 102000000018 Chemokine CCL2 Human genes 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010058861 Fibrin Fibrinogen Degradation Products Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 101150001754 Gusb gene Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101100055111 Homo sapiens AHNAK2 gene Proteins 0.000 description 1
- 101100055638 Homo sapiens ANXA10 gene Proteins 0.000 description 1
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 description 1
- 101000614436 Homo sapiens Keratin, type I cytoskeletal 14 Proteins 0.000 description 1
- 101000938676 Homo sapiens Liver carboxylesterase 1 Proteins 0.000 description 1
- 101001005722 Homo sapiens Melanoma-associated antigen 6 Proteins 0.000 description 1
- 101001000104 Homo sapiens Myosin-11 Proteins 0.000 description 1
- 101001067833 Homo sapiens Peptidyl-prolyl cis-trans isomerase A Proteins 0.000 description 1
- 101000931462 Homo sapiens Protein FosB Proteins 0.000 description 1
- 101000688348 Homo sapiens Protein phosphatase 1 regulatory subunit 14C Proteins 0.000 description 1
- 101000575639 Homo sapiens Ribonucleoside-diphosphate reductase subunit M2 Proteins 0.000 description 1
- 101000629631 Homo sapiens Sorbin and SH3 domain-containing protein 1 Proteins 0.000 description 1
- 101000880098 Homo sapiens Sushi repeat-containing protein SRPX Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 102100040445 Keratin, type I cytoskeletal 14 Human genes 0.000 description 1
- 101710183663 Keratin, type I cytoskeletal 20 Proteins 0.000 description 1
- 108010066370 Keratin-20 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102100030817 Liver carboxylesterase 1 Human genes 0.000 description 1
- 101150067233 MAGEA3 gene Proteins 0.000 description 1
- 101150036749 Mcm10 gene Proteins 0.000 description 1
- 102100025075 Melanoma-associated antigen 6 Human genes 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102100036639 Myosin-11 Human genes 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100020847 Protein FosB Human genes 0.000 description 1
- 101710081976 Protein phosphatase 1 regulatory subunit 14D Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 101100397619 Rattus norvegicus Krt20 gene Proteins 0.000 description 1
- 102100026006 Ribonucleoside-diphosphate reductase subunit M2 Human genes 0.000 description 1
- 101710102802 Runt-related transcription factor 2 Proteins 0.000 description 1
- 101150045248 Slc1a6 gene Proteins 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 102100026834 Sorbin and SH3 domain-containing protein 1 Human genes 0.000 description 1
- 102100037352 Sushi repeat-containing protein SRPX Human genes 0.000 description 1
- 101150047500 TERT gene Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000012349 Uroplakins Human genes 0.000 description 1
- 108010061861 Uroplakins Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000007635 classification algorithm Methods 0.000 description 1
- 238000013145 classification model Methods 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 101150070926 ct gene Proteins 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000208 fibrin degradation product Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 1
- 238000013277 forecasting method Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000057877 human IGF2 Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940068935 insulin-like growth factor 2 Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000000260 male genitalia Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229940101532 meted Drugs 0.000 description 1
- 238000012775 microarray technology Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 208000011252 penile benign neoplasm Diseases 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 238000001303 quality assessment method Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011470 radical surgery Methods 0.000 description 1
- 230000031539 regulation of cell division Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000014794 superficial urinary bladder carcinoma Diseases 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 108010057210 telomerase RNA Proteins 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 208000029584 urinary system neoplasm Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
Definitions
- CTSE cathepsin E gene (also called CATE), located at 1q31, codes for an intracellular protease.
- the KLF9 gene (Kruppel-like factor 9) (also called BTEB1), codes for a transcription factor.
- said diagnostic and / or prognostic method is contemplated based on the detection and individual quantification of the expression of the POSTN gene.
- the bladder cancer diagnosis and / or prognosis kit comprises a set of probes suitable for the detection and quantification of the expression pattern of the combination of ANXA10, CTSE, CRH, IGF2, KRT20, MAGEA3 genes,
- the probes were synthesized by a direct mareaje method
- the final objective of this study was to select a reduced set of bladder-related CCT genes and to quantify their expression, diagnostic and prognostic information was obtained from the tumor.
- DNA microarrays By means of microarray technology thousands of genes are tested in each experiment and a greater quantity of RNA and of better quality is needed to perform the experiments than with the qRT-PCR methodology.
- the latter is a more precise technology and the exact number of genes of interest can be quantified. Therefore, it was decided to use the TaqMan Low Density Arrays (TLDA) technology, based on qRT-PCR, in the following phases of the study.
- TLDA TaqMan Low Density Arrays
- bladder fluids are sub-grouped into a set of samples that grouped in the upper part of the cluster (from sample B155-RV_T2alto to B288-RV1_TaG2alto) and that is formed only by samples of tumor bladder fluids, and another set of samples in the lower part of the cluster (from sample B71- RV_TaG2bajoCIS to Ia B109-RV_T2alto) which is formed by a mixture of tumor bladder fluids and controls.
- the upper cluster we can differentiate between high-grade and low-grade tumors, while in the lower one there is a cluster with almost only control samples and another with a mixture of controls and tumors. It has to be taken into account that it has gone from analyzing tissue in poles to bladder fluids in individual samples, so this loss of discrimination power by cluster was relatively predictable.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- External Artificial Organs (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200780053065A CN101730848A (zh) | 2007-03-20 | 2007-06-05 | 膀胱癌诊断和/或预后方法 |
EP07788578A EP2138848B1 (en) | 2007-03-20 | 2007-06-05 | Method for the diagnosis and/or prognosis of cancer of the bladder |
PL07788578T PL2138848T3 (pl) | 2007-03-20 | 2007-06-05 | Sposób diagnozowania i/lub prognozowania raka pęcherza moczowego |
AT07788578T ATE487140T1 (de) | 2007-03-20 | 2007-06-05 | Verfahren zur diagnose und/oder prognose von blasenkrebs |
CA2693847A CA2693847C (en) | 2007-03-20 | 2007-06-05 | Bladder cancer diagnosis and/or prognosis method |
JP2010500299A JP5314667B2 (ja) | 2007-03-20 | 2007-06-05 | 膀胱癌の診断および/または予後方法 |
US12/532,139 US9097715B2 (en) | 2007-03-20 | 2007-06-05 | Bladder cancer diagnosis and/or prognosis method |
DE602007010360T DE602007010360D1 (de) | 2007-03-20 | 2007-06-05 | Verfahren zur diagnose und/oder prognose von blasenkrebs |
DK07788578.8T DK2138848T3 (da) | 2007-03-20 | 2007-06-05 | Fremgangsmåde til diagnose og/eller prognose af blærecancer |
SI200730488T SI2138848T1 (sl) | 2007-03-20 | 2007-06-05 | Postopek za diagnozo in/ali prognozo raka mehurja |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP200700727 | 2007-03-20 | ||
ES200700727A ES2304306B1 (es) | 2007-03-20 | 2007-03-20 | Metodo de diagnostico y/o pronostico de cancer vesical. |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008113870A1 true WO2008113870A1 (es) | 2008-09-25 |
Family
ID=39758544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2007/000330 WO2008113870A1 (es) | 2007-03-20 | 2007-06-05 | Método de diagnóstico y/o pronóstico de cancer vesical |
Country Status (13)
Country | Link |
---|---|
US (1) | US9097715B2 (es) |
EP (1) | EP2138848B1 (es) |
JP (1) | JP5314667B2 (es) |
CN (1) | CN101730848A (es) |
AT (1) | ATE487140T1 (es) |
CA (1) | CA2693847C (es) |
DE (1) | DE602007010360D1 (es) |
DK (1) | DK2138848T3 (es) |
ES (2) | ES2304306B1 (es) |
PL (1) | PL2138848T3 (es) |
PT (1) | PT2138848E (es) |
SI (1) | SI2138848T1 (es) |
WO (1) | WO2008113870A1 (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2762574A1 (en) | 2013-01-31 | 2014-08-06 | Fina Biotech, S.L. | Non-invasive diagnostic method for diagnosing bladder cancer |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3013992A1 (en) * | 2008-12-30 | 2010-07-08 | Children's Medical Center Corporation | Method of predicting acute appendicitis |
US20120053253A1 (en) * | 2010-07-07 | 2012-03-01 | Myriad Genetics, Incorporated | Gene signatures for cancer prognosis |
BR112013001637A2 (pt) * | 2010-07-22 | 2016-05-24 | Glaxosmithkline Biolog Sa | proteína ligadora de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, métodos para produção de proteína ligadora de antígeno, e para detectar mage-a3 e/ou mage-a6 em tecido de humano fixado com formalina e infiltrado em parafina. |
EP2663656B1 (en) * | 2011-01-13 | 2016-08-24 | Decode Genetics EHF | Genetic variants as markers for use in urinary bladder cancer risk assessment |
EP2723898A4 (en) * | 2011-06-22 | 2015-09-30 | Oncocyte Corp | METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF BUBBLE CANCER |
US9249467B2 (en) * | 2011-09-16 | 2016-02-02 | Steven Goodison | Bladder cancer detection composition, kit and associated methods |
WO2013040758A1 (zh) * | 2011-09-20 | 2013-03-28 | 深圳华大基因科技有限公司 | 膀胱移行细胞癌易感性的相关基因及其预测方法和系统 |
JP2014533493A (ja) * | 2011-11-15 | 2014-12-15 | オンコサイト コーポレーション | 膀胱癌の処置および診断のための方法および組成物 |
ES2601460T3 (es) | 2011-12-30 | 2017-02-15 | Abbott Molecular Inc. | Materiales y métodos para el diagnóstico del cáncer de vejiga y el control de la recurrencia del mismo |
WO2013158972A1 (en) * | 2012-04-20 | 2013-10-24 | Cepheid | Methods of detecting bladder cancer |
US10329622B2 (en) | 2013-03-06 | 2019-06-25 | Cepheid | Methods of detecting bladder cancer |
WO2015013233A2 (en) * | 2013-07-23 | 2015-01-29 | Oncocyte Corp | Methods and compositions for the treatment and diagnosis of bladder cancer |
US10304188B1 (en) | 2015-03-27 | 2019-05-28 | Caleb J. Kumar | Apparatus and method for automated cell analysis |
US11519916B2 (en) | 2015-06-08 | 2022-12-06 | Arquer Diagnostics Limited | Methods for analysing a urine sample |
ES2911415T3 (es) | 2015-06-08 | 2022-05-19 | Arquer Diagnostics Ltd | Métodos y kits |
WO2017021501A1 (en) * | 2015-08-06 | 2017-02-09 | Stichting Katholieke Universiteit | Method for the prediction of progression of bladder cancer |
CN105368959B (zh) * | 2015-12-15 | 2019-01-04 | 甘肃中天羊业股份有限公司 | Anxa10基因作为绵羊免疫性状的分子标记及其应用 |
WO2018219342A1 (zh) * | 2017-06-01 | 2018-12-06 | 立森印迹诊断技术有限公司 | 一种印记基因分级模型和诊断方法及其应用 |
WO2018218737A1 (zh) * | 2017-06-01 | 2018-12-06 | 立森印迹诊断技术(无锡)有限公司 | 一种印记基因在膀胱肿瘤中的分级模型及其组成的系统 |
CN108414756A (zh) * | 2017-10-25 | 2018-08-17 | 深圳市罗湖区人民医院 | 一种同时检测尿液中四个膀胱癌标志物的蛋白芯片的制备方法 |
CN108414755A (zh) * | 2017-10-25 | 2018-08-17 | 深圳市罗湖区人民医院 | 一种同时检测尿液中四个膀胱癌标志物的蛋白芯片 |
CN108866194B (zh) | 2018-08-16 | 2021-03-26 | 杭州可帮基因科技有限公司 | 一组用于膀胱癌检测的基因及其应用 |
CN109797221A (zh) * | 2019-03-13 | 2019-05-24 | 上海市第十人民医院 | 一种用于对肌层浸润性膀胱癌进行分子分型和/或预后预测的生物标记物组合及其应用 |
CN112378708B (zh) * | 2020-11-04 | 2024-03-26 | 中国人民解放军陆军装甲兵学院 | 一种基于Bayes方法小样本条件下装备评估装置 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1318504B1 (it) * | 2000-05-08 | 2003-08-27 | Talent Srl | Metodo e apparecchiatura per la diagnosi precoce di tumori vescicalisu campioni di urina. |
-
2007
- 2007-03-20 ES ES200700727A patent/ES2304306B1/es not_active Expired - Fee Related
- 2007-06-05 DK DK07788578.8T patent/DK2138848T3/da active
- 2007-06-05 WO PCT/ES2007/000330 patent/WO2008113870A1/es active Application Filing
- 2007-06-05 US US12/532,139 patent/US9097715B2/en active Active
- 2007-06-05 SI SI200730488T patent/SI2138848T1/sl unknown
- 2007-06-05 AT AT07788578T patent/ATE487140T1/de active
- 2007-06-05 EP EP07788578A patent/EP2138848B1/en active Active
- 2007-06-05 CN CN200780053065A patent/CN101730848A/zh active Pending
- 2007-06-05 CA CA2693847A patent/CA2693847C/en active Active
- 2007-06-05 ES ES07788578T patent/ES2357784T3/es active Active
- 2007-06-05 DE DE602007010360T patent/DE602007010360D1/de active Active
- 2007-06-05 PT PT07788578T patent/PT2138848E/pt unknown
- 2007-06-05 PL PL07788578T patent/PL2138848T3/pl unknown
- 2007-06-05 JP JP2010500299A patent/JP5314667B2/ja not_active Expired - Fee Related
Non-Patent Citations (43)
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2762574A1 (en) | 2013-01-31 | 2014-08-06 | Fina Biotech, S.L. | Non-invasive diagnostic method for diagnosing bladder cancer |
WO2014118334A1 (en) | 2013-01-31 | 2014-08-07 | Fina Biotech, S.L | Non-invasive diagnostic method for diagnosing bladder cancer |
US9902998B2 (en) | 2013-01-31 | 2018-02-27 | Fina Biotech, S.L. | Non-invasive diagnostic method for diagnosing bladder cancer |
EP4060048A2 (en) | 2013-01-31 | 2022-09-21 | Fina Biotech, S.L. | Non-invasive diagnostic method for diagnosing bladder cancer |
Also Published As
Publication number | Publication date |
---|---|
ES2357784T3 (es) | 2011-04-29 |
DE602007010360D1 (de) | 2010-12-16 |
ES2304306B1 (es) | 2009-07-07 |
PL2138848T3 (pl) | 2011-11-30 |
ATE487140T1 (de) | 2010-11-15 |
CA2693847A1 (en) | 2008-09-25 |
CA2693847C (en) | 2016-08-02 |
ES2304306A1 (es) | 2008-10-01 |
JP5314667B2 (ja) | 2013-10-16 |
EP2138848A4 (en) | 2010-03-31 |
DK2138848T3 (da) | 2011-02-21 |
EP2138848A1 (en) | 2009-12-30 |
PT2138848E (pt) | 2011-02-08 |
US20100086932A1 (en) | 2010-04-08 |
SI2138848T1 (sl) | 2011-04-29 |
EP2138848B1 (en) | 2010-11-03 |
US9097715B2 (en) | 2015-08-04 |
JP2010521981A (ja) | 2010-07-01 |
CN101730848A (zh) | 2010-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2357784T3 (es) | Procedimiento de diagnóstico y/o pronóstico de cáncer vesical. | |
ES2494843T3 (es) | Métodos y materiales para identificar el origen de un carcinoma de origen primario desconocido | |
Chakraborty et al. | Current status of molecular markers for early detection of sporadic pancreatic cancer | |
US9902998B2 (en) | Non-invasive diagnostic method for diagnosing bladder cancer | |
US7670775B2 (en) | Method for differentiating malignant from benign thyroid tissue | |
US20170073758A1 (en) | Methods and materials for identifying the origin of a carcinoma of unknown primary origin | |
US20070099197A1 (en) | Methods of prognosis of prostate cancer | |
ES2608322T3 (es) | Procedimiento para predecir la respuesta a la quimioterapia en un paciente que padece o está en riesgo de desarrollar cáncer de mama recurrente | |
US20200172980A1 (en) | Prostatic cancer marker, pcdh9, and application thereof | |
US20090215058A1 (en) | Methods for screening, predicting and monitoring prostate cancer | |
WO2006124022A1 (en) | Microarray gene expression profiling in subtypes of clear cell renal cell carcinoma | |
EP2373816B1 (en) | Methods for screening, predicting and monitoring prostate cancer | |
KR20220131083A (ko) | 갑상선암 진단을 위한 microRNA 바이오마커 및 이의 용도 | |
Oliveira-Cunha et al. | Poly (adenylic acid) complementary DNA real-time polymerase chain reaction in pancreatic ductal juice in patients undergoing pancreaticoduodenectomy | |
AU2015203005B2 (en) | A method of diagnosing neoplasms | |
JP2004248508A (ja) | 膀胱癌に対する分子マーカーとしてのhurp遺伝子 | |
WO2023015286A1 (en) | Gene/protein expression guided melanoma surgery | |
Vasileva et al. | Detection of GSTP1 Hypermethylation and Hepsin Activity for Prostate Non-Invasive Cancer Diagnostics | |
Hessels et al. | Detection of TMPRSS2-ERG fusion transcripts and PCA3 in urinary sediments may improve diagnosis of prostate cancer | |
Troyer et al. | Quantitation of TMPRSS2: ERG fusion transcripts in frozen and paraffin embedded prostate cancers (PC) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780053065.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07788578 Country of ref document: EP Kind code of ref document: A1 |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2693847 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2010500299 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3383/KOLNP/2009 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007788578 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12532139 Country of ref document: US |